MEK Inhibitors Reverse Growth of Embryonal Brain Tumors Derived from Oligoneural Precursor Cells

Highlights

- Subsets of CNS-PNETs express oligodendrocyte precursor cell genes SOX10 and OLIG2
- Activating NRAS/MAPK signaling in OPCs generates CNS-PNET-like tumors in zebrafish
- Cancer genomes of zebrafish and human NB-FOXR2 CNS-PNETs are highly conserved
- MEK inhibitors are identified as a potential treatment for oligoneural/NB-FOXR2 CNS-PNETs

In Brief

Modzelewska et al. generate a zebrafish model of CNS-PNET driven by NRAS activation in Olig2+/Sox10+ oligoneural precursor cells. Molecular and genomic analyses show that the zebrafish brain tumors closely resemble the oligoneural/NB-FOXR2 CNS-PNET subgroup. Finally, an embryonic brain tumor transplantation assay designed to screen drugs shows that MEK inhibitors can eradicate these tumors in vivo.

Accession Numbers

GSE80768

Authors

Katarzyna Modzelewska, Elena F. Boer, Timothy L. Mosbruger, ..., Cicely A. Jette, Annie Huang, Rodney A. Stewart

Correspondence

rodney.stewart@hci.utah.edu

Modzelewska et al., 2016, Cell Reports 17, 1255–1264

October 25, 2016 © 2016 The Author(s).

http://dx.doi.org/10.1016/j.celrep.2016.09.081
MEK Inhibitors Reverse Growth of Embryonal Brain Tumors Derived from Oligoneural Precursor Cells


INTRODUCTION

Pediatric tumors of the CNS are the leading cause of cancer-related deaths in children under 14 years of age. The most common pediatric brain tumors can be broadly defined as glial-like (such as astrocytoma) or embryonal-like (such as medulloblastoma [MB]) and are thought to arise from glial or multi-potent progenitors, respectively. Primitive neuroectodermal tumors of the CNS (CNS-PNETs) are embryonal tumors that comprise a complex group of highly malignant pediatric brain tumors with similar histology but diverse clinical behaviors (Adamski et al., 2014; Chan et al., 2015). Histologically, CNS-PNETs closely resemble cerebellar MB, but only comprise ~10% of MB cases, and are often localized in the cerebral hemispheres (Chan et al., 2015). The lack of robust diagnostic markers combined with the rare occurrence of CNS-PNETs often leads to misdiagnosis and treatment with heterogeneous regimens, which likely contributes to the dismal overall survival of CNS-PNET patients despite aggressive treatments that include surgery, radiation, and chemotherapy. Indeed, CNS-PNET patients have a 5-year overall survival rate of 20%–40%, in contrast to 60%–65% observed in high-risk metastatic MB (Chan et al., 2015). Clearly, new treatments are needed to improve survival and morbidity in children with CNS-PNETs.

Recent comparative genomic analysis has classified CNS-PNETs into distinct subgroups with unique molecular signatures and/or genetic aberrations (Picard et al., 2012; Sturm et al., 2016). These studies promise to improve diagnosis and guide the use of more selective, subgroup-specific therapies that both increase patient survival and alleviate long-term cognitive and physical side effects. However, a current barrier to identifying such treatments is the lack of cell- or animal-based models of CNS-PNET subgroups to test potential therapies, which is likely due to both the rarity of these tumors and the lack of defined cellular origins and oncogenic drivers for each subgroup. Here, we present a genetically engineered animal model of the CNS-PNET subgroup that is defined by the expression of oligoneural precursor cell (OPC) genes, such as OLIG2 and SOX10, previously referred to as oligoneural PNET (Picard et al., 2012) or CNS_NB-FOXR2 (Sturm et al., 2016). We show that SOX10-expressing OPCs represent an origin of the oligoneural CNS-PNET subgroup by activating NRAS/MAPK (mitogen-activated protein kinase) signaling in these cells. The zebrafish CNS-PNET-like tumors show conservation of histopathology (small round neuroblastic cells of primitive neuroectodermal origin) and hallmarks of the oligoneural CNS-PNET subtype, including

SUMMARY

Malignant brain tumors are the leading cause of cancer-related deaths in children. Primitive neuroectodermal tumors of the CNS (CNS-PNETs) are particularly aggressive embryonal tumors of unknown cellular origin. Recent genomic studies have classified CNS-PNETs into molecularly distinct subgroups that promise to improve diagnosis and treatment; however, the lack of cell- or animal-based models for these subgroups prevents testing of rationally designed therapies. Here, we show that a subset of CNS-PNETs co-express oligoneural precursor cell (OPC) markers OLIG2 and SOX10 with coincident activation of the RAS/MAPK (mitogen-activated protein kinase) pathway. Modeling NRAS activation in embryonic OPCs generated malignant brain tumors in zebrafish that closely mimic the human oligoneural CNS-PNET subgroup by histology and comparative oncogenomics. The zebrafish CNS-PNET model was used to show that MEK inhibitors selectively eliminate Olig2+/Sox10+ CNS-PNET tumors in vivo without impacting normal brain development. Thus, MEK inhibitors represent a promising rationally designed therapy for children afflicted with oligoneural/NB-FOXR2 CNS-PNETs.
Sox10 and Olig2 co-expression. Comparative genomic analysis also revealed remarkable conservation between the molecular signaling pathways and differentiation states of zebrafish and human oligoneural/NB-FOXP2 CNS-PNETs. Finally, we describe a drug-screening platform using orthotopic embryonic brain tumor transplantation in immune-competent animals to rapidly screen drugs that eliminate these highly aggressive tumors without affecting the development of the rest of the animal and identify MEK inhibitors as a promising therapeutic option for selectively eliminating OLIG2/SOX10-expressing CNS-PNETs in children. Thus, the zebrafish brain tumor modeling and drug treatment approaches outlined here, combined with its well-established embryology and imaging properties, provide a powerful and rapid in vivo method of identifying conserved developmental, cellular, and molecular mechanisms in childhood brain cancers, as well as accelerating subgroup-specific drug discovery through whole-animal-based, small-molecule screening.

RESULTS AND DISCUSSION

A Subset of Human CNS-PNETs Express OPC Markers Coincident with Activation of MAPK Signaling

Recent studies identified a subset of CNS-PNETs with elevated expression of OLIG2 and SOX10 mRNA (Picard et al., 2012; Sturm et al., 2016), a combination typically restricted to embryonic OPCs and oligodendrocytes during brain and CNS development (Weider and Wegner, 2016). Consistent with these findings, analysis of CNS-PNET gene expression datasets (Li et al., 2009) showed that 8/26 CNS-PNETs co-expressed elevated levels of SOX10 and OLIG2 mRNA (Figure S1A), a significant correlation (p < 0.0001) for this class of pediatric brain tumors (Figure S1B). Analysis of an MB gene expression dataset (Kool et al., 2008) also showed that a small fraction of MBs co-expressed OLIG2 and SOX10 mRNA (Figure S1C); however, this correlation was not significant (Figure S1B). To determine whether OLIG2 and SOX10 proteins are co-expressed in CNS-PNETs and MB, we performed immunohistochemical (IHC) analysis on four CNS-PNETs and 52 MB patient samples, which showed co-expression in one of four CNS-PNETs and 1 of 52 MB samples (Figure S1D). Together, these findings show that approximately 25%-30% of embryonal CNS-PNET tumors, and some rare MBs, co-express SOX10 and OLIG2 in cells that maintain the histological morphology of undifferentiated glial progenitors such as OPCs.

CNS-PNETs that co-express OLIG2 and SOX10 have significantly elevated ERBB3 mRNA levels (Figures S1A and S1E). As ERBB3 is an upstream activator of RAS GTPases (Hynes and MacDonald, 2009), we next determined whether the RAS/MAPK signaling pathway was activated in OLIG2*/SOX10* double-positive tumors. Gene set enrichment analysis (GSEA) of OLIG2*/SOX10* expressing CNS-PNET tumors compared to all other CNS-PNETs revealed a significantly enriched RAS pathway signature (Figure S1F). Consistent with these findings, phosphorylated MAPK (pMAPK) levels were elevated in human CNS-PNET and MB tumor samples co-expressing OLIG2 and SOX10 (Figure S1D). Elevated pMAPK staining was also observed in two additional CNS-PNETs and nine MBs (as represented in Figure S1D). These studies suggest that a subset of human CNS-PNETs and MBs may be driven by activation of the MAPK pathway, a finding consistent with previous studies showing RAS/MAPK pathway activation in MB (Gilbertson et al., 2006; MacDonald et al., 2001).

Oncogenic and Wild-Type NRAS Expression in OPCs Induces CNS Tumors in Zebrafish

To functionally test whether CNS-PNETs could originate from OPCs with RAS/MAPK activation, we generated DNA constructs that drive human NRAS expression in embryonic OPCs using an established sox10 promoter (Kirby et al., 2009). NRAS was either oncogenic with a GTPase-activating mutation [Tg(sox10:mCherry-NRASQ61R)], wild-type (WT) [Tg(sox10:mCherry-NRASWT)], or disabled with a GTPase-inactivating mutation [Tg(sox10:mCherry-NRAS(G201R))] in lateral views of 24-hpf embryos to confirm injection efficiency. Only embryos that expressed mCherry at 24 hpf were raised for tumor and survival analysis in (C)-(E), but not all mCherry-expressing 24-hpf embryos would eventually develop tumors. Middle (bright-field) and bottom (mCherry) panels show a tumor mass arising in the head in (B) Top panels show detection of chimeric expression of sox10:mCherry-NRAS constructs in (B)-(F).

Figure 1. Oncogenic and WT NRAS Drive CNS Tumors in Zebrafish

(A) Schematic of DNA constructs injected into one-cell-stage mitta10; p53MG21+K embryos and timeline for injections and screening of tumors arising from mosaic expression of the sox10:mCherry-NRAS constructs in (B)-(F).

(B) Top panels show detection of chimeric expression of sox10:mCherry-NRAS constructs by immunofluorescence in lateral views of 24-hpf embryos to confirm injection efficiency. Only embryos that expressed mCherry at 24 hpf were raised for tumor and survival analysis in (C)-(E), but not all mCherry-expressing 24-hpf embryos would eventually develop tumors. Middle (bright-field) and bottom (mCherry) panels show a tumor mass arising in the head in NRASQ61R- and NRASWT-expressing fish but not NRASG201R-expressing fish.

(C) Percentage of mitta10; p53MG21+K embryos injected with one of the indicated constructs that went on to develop tumors after 6 weeks (arrow).

(D) Survival of tumor-bearing mitta10; p53MG21+K animals injected with indicated constructs analyzed after 4 weeks post-injection (arrow).

(E) p53 dependence of NRASG201R-driven tumors. The Tg(sox10:mCherry-NRASG201R) construct was injected into embryos derived from an incross between mitta10; p53MG21+K fish and analyzed for survival. Representative results from three independent injections are shown in (C)-(E).

(F) Top left: schematic of zebrafish brain with forebrain and midbrain regions shaded gray, while cerebellum and brain stem are white. Olfactory bulb (OB) and telencephalon (Te) are indicated. Vertical (stippled) and horizontal (dashed) lines indicate the locations of transverse and sagittal histological sections in histology at the bottom right. Top right: NRASQ61R-driven brain tumors arise equally in the indicated compartments of the zebrafish brain. Averages correspond to two independent experiments, both of which gave rise to values of 50%. Forebrain or midbrain (gray bar) is indicated by gray shading, and cerebellum or brain stem (white bar) is indicated by white shading in schematic. Bottom: tumors arising in the optic tectum or cerebellum were detected by directly visualizing mCherry and confirmed by histology on indicated sections (black arrows show location of tumors). See also Figure S1.
were also homozygous for the mitfa
\textsuperscript{W2} mutation that eliminates pigment (melanophore)
formation (Lister et al., 1999). By 6 weeks post-fertilization (wpf), mitfa
\textsuperscript{W2}, pS3\textsuperscript{M214K}, Tg sox10: mCherry-
NRAS\textsuperscript{G12R}) embryos displayed CNS tumors at a frequency of
\textasciitilde;50% (Figure 1C). Surprisingly, we observed CNS tumors at a
similar penetrance in mitfa
\textsuperscript{W2}, pS3\textsuperscript{M214K}, Tg sox10: mCherry-
NRAS\textsuperscript{Q61R}) zebrafish (Figure 1C), although tumors induced by acti-
vated NRAS\textsuperscript{Q61R} were more aggressive and showed poorer
overall survival (Figure 1D). Importantly, the expression of
GTPase-disabled NRAS [mitfa
\textsuperscript{W2}, pS3\textsuperscript{M214K}, Tg sox10: mCherry-
NRAS\textsuperscript{Q61R}] did not give rise to tumors (Figure 1C), indicating
that activation of downstream NRAS effectors is still required for
mitfa
\textsuperscript{W2}, pS3\textsuperscript{M214K}, Tg sox10: mCherry-NRAS\textsuperscript{Q61R}-induced
oncogenesis. Loss of p53 function was also a critical component
(Figure 1E). These data suggest that uncontrolled expression of
WT NRAS in embryonic neural stem cell populations may be suf-
ficient to drive tumorigenesis in a subset of human pediatric brain
tumors. Consistent with this notion, examination of NRAS mRNA
levels in published human tumor databases (https://www.
oncome.org) showed that NRAS mRNA is highly expressed in
a number of embryonal brain tumors when compared to normal brain:
MB (36–50-fold), CNS PNET (51-fold), and atypical teratoid/rhabdoid
tumors (AT/RTs, 250-fold) (Pomeroy et al., 2002). Thus, our finding that elevated WT NRAS, together with
p53 deficiency, is sufficient for CNS-PNET tumorigenesis may provide
at least one possible explanation for why mutations in
RAS/MAPK pathway components are rarely observed in pediatric
brain tumors, despite reports that these tumors exhibit robust
RAS/MAPK pathway activation (Gilbertson et al., 2006; Sturm et al., 2016). Future sequencing analysis in CNS-PNET patient
samples may identify additional mechanisms for RAS/MAPK
activation in CNS-PNETs (e.g., NF1 loss, SOS gain) and deter-
mine whether mutations in additional p53 pathway components
are associated with RAS/MAPK activation, as predicted by this model.

**Zebrafish Brain Tumor Histology and Location Are
Consistent with Human CNS-PNETs**

Pediatric CNS-PNET tumors are primarily diagnosed based on
location, H&E-based cell morphology, and specific IHC markers
(Chan et al., 2015; Louis et al., 2007). Tumors that are composed of
small blue cells and localized in the cerebrum, brain stem, or
spinal cord are likely to be diagnosed as CNS-PNETs, or as
AT/RTs if they lack
expression of markers commonly used to diagnose human
CNS-PNETs, including nestin, synaptophysin, and focal Gfap
(glial fibrillary acidic protein) staining (Figure 2A). Tumors also
stained positive for Ini1 (Snf5/Smarcb1), which excluded the
possibility that they are AT/RTs (Figure 2A) (Chan et al., 2015).
Thus, based on histology, the NRAS\textsuperscript{WT}-driven tumors arising
from the anterior compartments most closely resemble human
CNS-PNETs.

To determine whether the NRAS\textsuperscript{WT}-driven CNS-PNET-like tu-
mors display OPC characteristics, we analyzed Olig2 and Sox10
tumors and detected strong positive staining (Figure 2A). The
tumors also expressed NRAS (derived from the transgene) and
pMAPK (Figure 2A). To complement our IHC analyses, we also
performed live confocal imaging in zebrafish fluorescent reporter
tissues to visualize Olig2-positive (GFP+) cells and Sox10-driven
mCherry-NRAS within developing tumors (Figure 2B). This anal-
ysis showed that mCherry-NRAS\textsuperscript{WT} and GFP were co-ex-
pressed in tumor cells with a rounded cellular morphology
consistent with the primitive neuroblastic appearance detected
by histology, while in adjacent normal brain tissue, GFP was ex-
pressed in oligodendrocytes with typical elongated and dendritic
morphology (Figure 2B).

**Genomic Analysis Shows Zebrafish Brain Tumors
Genetically Resemble Human CNS-PNETs**

To determine whether the zebrafish CNS-PNET-like tumors resemble human CNS-PNET tumors at the genetic level, we
compared gene expression signatures between zebrafish
NRAS\textsuperscript{WT}-driven tumors and human CNS-PNETs. We first per-
formed RNA sequencing (RNA-seq) analysis on NRAS\textsuperscript{WT}-ex-
pressing zebrafish brain tumors derived from the anterior
compartments, as well as normal brain tissue, and identified
differentially expressed gene signatures indicative of signaling
pathway activation by GSEA (Figure 3A). The analysis was pre-
dictive of an embryonic progenitor origin, with significant enrichment
for genes expressed in pediatric tumors, embryonic stem (ES)
cells, and the epithelial-to-mesenchymal transition (EMT),
while gene sets for differentiated neurons and synaptic transmis-
sion were negatively enriched (Figure 3A, see the neuronal gene
set). Oncogenic signatures revealed enrichment for genes regu-
lated by the epidermal growth factor (EGFR) pathway (Figure 3A),
which is consistent with the prevalence of pMAPK in the human
CNS-PNETs (Figure S1D). In addition, the zebrafish tumors likely
have a dysfunctional retinoblastoma (Rb) 1 (Rb1) pathway, since
gene sets predictive of Rb1 loss and E2F transcription factor
activation were significantly enriched (Figure 3A), consistent
with the occurrence of CNS-PNETs in some Rb patients (Li et al., 2005) and loss of Rb causing embryonal-like brain
tumors in mouse and zebrafish (Jacques et al., 2010; Saab et al., 2009;
Solin et al., 2015).
Human CNS-PNETs have recently been stratified based on gene expression analysis, with high levels of both OLIG2 and SOX10 associated with the oligoneural (Picard et al., 2012) or CNS_NB-FOXR2 (Sturm et al., 2016) subgroups (Figure S2A). To determine whether the zebrafish CNS-PNET-like tumors resemble these specific subtypes, we performed comparative genomic analysis between human and zebrafish tumors (Figure 3B; Table S1). We first identified the top 60 up- or downregulated genes in OLIG2/SOX10 co-expressing human tumors compared to normal human brain (Li et al., 2009) and compared this list to the differentially expressed genes in zebrafish CNS-PNET-like tumors compared to normal zebrafish brain (see Experimental Procedures). This analysis showed that zebrafish CNS-PNET-like tumors share a highly conserved gene expression signature with the human oligoneural CNS-PNET subtype (Figure 3B). Furthermore, when we compared the zebrafish CNS-PNET-like tumors to all human CNS-PNET brain tumor subgroups using principal-component analysis (PCA) with published gene lists (Picard et al., 2012; Sturm et al., 2016), we found that the zebrafish tumors are most similar to the oligoneural and NB-FOXR2 CNS-PNET subgroups (Figure 3C). We also found that the zebrafish CNS-PNET-like tumors are more similar to human oligoneural/NB-FOXR2 CNS-PNETs than zebrafish normal brain (Figure 3C). Consistent with the PCA findings, analysis of the recently described CNS_NB-FOXR2 subgroup (Sturm et al., 2016) showed that these tumors also have significant correlation with elevated expression of SOX10/OLIG2 (p < 0.0001) and ERBB3 (p < 0.0001) and positively enriched for RAS/MAPK pathway activation by GSEA (Figures S2B–S2D). These data suggest that the oligoneural CNS-PNET (Picard et al., 2012) and CNS_NB-FOXR2 (Sturm et al., 2016) subgroups represent a single tumor entity in humans that can be distinguished from other CNS-PNET subgroups by high SOX10/OLIG2 co-expression. Importantly, these analyses indicate that zebrafish CNS-PNET-like brain tumors represent an animal model for the oligoneural/NB-FOXR2 CNS-PNET subgroup.

Orthotopic Tumor Transplantation Assay Identifies MEK Inhibitors as Potential Therapies for OLIG2/SOX10-Expressing CNS-PNETs

There are no established cell lines or animal models of the oligoneural/NB-FOXR2 CNS-PNET subtype, which limits our ability to discover new therapies that specifically target these tumors. Therefore, we used the zebrafish oligoneural CNS-PNET model...
to identify potential therapies for OLIG2/SOX10-expressing CNS-PNET tumors. We first developed an orthotopic tumor cell transplantation method using embryonic zebrafish at 2 days post-fertilization (dpf) that allows the rapid propagation and direct visualization of primary brain tumor cells into hundreds of embryos per day with 80%–90% engraftment efficiency, as the adaptive immune system has yet to mature at this stage (Figure 4A). Single-cell suspensions derived from NRAS<sup>WT</sup>-driven CNS-PNETs were delivered to the lumen of the fourth ventricle (Figure 4A). At 1 day post-transplantation, the tumor cells could be visualized by fluorescence microscopy within the developing brain tissue and cerebral spinal fluid (Figure 4A, 3 dpf, arrows). Transplanted tumors spread throughout the brain by 17 dpf and encompassed the entire brain by 7 dpf (Figure 4A).

Next, we developed a drug treatment regimen (Figure 4B) to test whether inhibition of the MAPK pathway could prevent tumor growth in vivo. The AZD6244 compound (ARRY-142886) is an established MEK inhibitor that is under clinical investigation for the treatment of multiple cancers, including childhood brain tumors (ClinicalTrials.gov: NCT01386450). A representative group of embryos were imaged prior to treatment (Figure 4C, 3 dpf). Embryos were then randomly divided into groups, treatments were initiated, and embryos were monitored daily for a 5-day period. Upon completion of treatments (8 dpf), embryos were imaged by fluorescence microscopy, and tumor area was quantified (Figure 4C). AZD6244-treated embryos exhibited a significantly smaller tumor burden post-treatment compared to DMSO-treated embryos (Figure 4C). Similar results were obtained with the MEK inhibitor U0126 (Figures S3A and S3B), DMSO- and inhibitor-treated embryos had similarly high survival rates during the course of the 5-day treatment (Figure 4D; Figure S3C). In addition, immunoblot staining from tumor lysates showed that MAPK phosphorylation was significantly diminished in the MEK-inhibitor-treated embryos (Figure 4E). To determine whether the AZD6244 treatment translated into a durable response, we next monitored the juvenile and adult fish from both AZD6244 and DMSO treatment groups weekly for 8 weeks. Remarkably, only 21% of the AZD6244-treated fish showed evidence of metastasis at 8 weeks post-treatment compared to 88% of the DMSO-treated fish (Figure 4F; Movies S1 and S2), and AZD6244-treated fish exhibited a significantly higher post-treatment survival (Figure 4D). In addition, many of the DMSO-treated tumors had metastasized throughout the spinal cord by 8 weeks post-treatment, while none of the AZD6244-treated tumor fish showed evidence of metastasis (Movies S1 and S2). These results show that MEK inhibitors are extremely effective at eliminating sox10/olig2-expressing CNS-PNET in vivo and, at the doses and times used, confer minimal toxicity to WT tissues.

In summary, we show that activation of NRAS signaling in sox10-expressing zebrafish OPCs drives the formation of CNS PNET-like tumors that share remarkable conservation with human oligoneural/NB-FOXO2 CNS-PNETs. We take advantage of the scalability and imaging properties of the zebrafish system to design a rapid drug-screening platform and show that MEK inhibitors potently and durably reverse CNS-PNET-like growth in vivo without obvious effects on other tissues, including the developing brain. Thus, our findings suggest that MEK inhibitors could be an effective therapeutic approach for children with embryonal tumors expressing SOX10 and OLIG2. Furthermore, these studies provide the foundation to rapidly evaluate potential genetic drivers of different CNS tumors in zebrafish, including candidate fusion oncogenes and epigenetic modifiers identified in large-scale genomic screens for MB and pediatric glioma (Pashos et al., 2013). Our phenotypic drug-screening platform also provides a complementary approach to allow rapid and inexpensive identification of compounds that reverse tumor growth, invasion and/or metastasis of brain cancers. Finally, the embryonic brain transplantation method could be readily modified to accommodate human cancer cells to generate patient-derived xenograph (PDX) models of childhood brain cancers for future small-molecule drug screening, similar to methods described for adult glioblastoma cell lines (Welker et al., 2016).

**EXPERIMENTAL PROCEDURES**

**Zebrafish Lines**

Zebrafish were maintained and bred as described previously (Westerfield, 1993), and all procedures were approved by the University of Utah Institutional Animal Care and Use Committee.

**Tumor Generation, Tumor Onset, and Survival**

At 24 hr post-injection of DNA constructs, embryos were screened and sorted for the expression of mCherry. Starting at 4–6 weeks, fish were screened weekly using a wide-fluorescence microscope for the onset of red tumor masses in the CNS. To generate survival curves, mitfa<sup>wt</sup>; p53<sup>Δ52Δ74Δ6K</sup> tumor-bearing fish injected with sox10:mCherry-NRAS<sup>WT</sup> (two sets, n = 69) or sox10:mCherry-NRAS<sup>Δ52Δ74Δ6K</sup> (three sets, n = 57) were monitored visually in tanks weekly and by fluorescence microscopy bi-weekly. Fish were sacrificed when tumor burden increased to approximately 20% of the total body size or impaired the animal’s ability to swim, feed, or behave normally. Thus, values plotted in the survival curve (Figure 1D) are determined by the date of sacrifice. For details about the injection procedure, preservation of culled fish, and experiments using mitfa<sup>wt</sup>; p53<sup>Δ52Δ74Δ6K</sup> fish, see Supplemental Experimental Procedures.

**Figure 3.** Zebrafish NRAS<sup>WT</sup>-Driven Tumors Show Gene Expression Signatures that Are Predictive of Oligoneural Progenitors and Pediatric Tumors

(A) Gene set enrichment analysis (GSEA) was performed on genes that were differentially expressed between NRAS<sup>WT</sup>-driven tumors and normal zebrafish brain (left) or genes that were differentially expressed between published human CNS-PNETs (GEO: GSE14295) and normal fetal brain (right). Gene sets identified in these analyses and their general biological categories are indicated to the left. NES, normalized enrichment score; FDR, false discovery rate; ES, embryonic stem; EMT, epithelial-mesenchymal transition.

(B) Heatmap showing gene expression in zebrafish NRAS<sup>WT</sup>-derived tumors and normal brain tissue arranged to highlight comparison to the top 60 genes up- and downregulated in human OLIG2/SOX10 CNS-PNETs compared to fetal brain. SOX10, OLIG2, and ERBB3 genes are highlighted.

(C) Principal-component analysis (PCA) showing zebrafish NRAS<sup>WT</sup>-derived tumors cluster with the OLIG2/SOX10-expressing human CNS-PNETs based on the oligoneural gene list generated by Picard et al. (2012) or the CNS_NB-FOXO2 gene list generated by Sturm et al. (2016). z, zebrafish; h, human. See also Figure S2 and Tables S1 and S2.
Figure 4. Drug Screens Using an Embryonic Brain Tumor Transplantation Assay Identify MEK as a Therapeutic Target for Oligoneuronal/NB-FOXr2 CNS-PNET-like Tumors

(A) Tumors derived from the anterior brain of mitfa<sup>−/−</sup>; p53<sup>M214K;</sup> Tg(sox10:mCherry-NRAS<sup>WT</sup>) transgenic fish were harvested and injected into the fourth ventricle (outlined in red) of a 2-dpf mitfa<sup>−/−</sup> embryo (top panels). The following day (3 dpf), successful injections were visualized by immunofluorescence, and some tumor cells could be found in the surrounding brain (arrows). By 17 dpf, tumor cells had proliferated and invaded the surrounding tissue. At 7 wpf, the tumor cells had spread throughout the brain.

(B) Schematic describing the timeline for the orthotopic embryonic transplantation method and drug treatment.

(C) Representative images of mCherry expression in embryos at 24 hr post-transplantation before treatment (3 dpf) and embryos treated daily for 5 days (8 dpf) with DMSO or MEK inhibitor AZD6244. Quantification of immunofluorescence on the final day of treatment (8 dpf) shows a significant decrease in the transplanted tumor mass in AZD6244-treated embryos compared to control.

(D) Survival analysis of embryos during drug treatment (3–8 dpf) shows that DMSO and AZD6244 do not cause significant toxicity at doses used, while survival analysis from 8 dpf to 9 wpf shows that AZD6244-treated embryos have significantly higher post-treatment survival (p = 0.045). Averages in (C) and (D) represent three independent experiments (±SEM) for each panel.

(E) Western blot showing that MEK inhibitors U0126 and AZD6244 inhibit Mapk signaling in zebrafish NRAS<sup>WT</sup>-driven brain tumor cells treated ex vivo. (For U0126 treatment results, see Figure S3).

(F) Representative images of the majority of 9-wpf adult fish at 8 weeks post-treatment (top) and quantification (bottom) from three independent experiments. Error bars represent ±SEM. See also Figure S3 and Movies S1 and S2.
Orthotopic Embryonic Transplants

Tumor cells were injected into the fourth ventricle of each embryo and then transferred into fresh egg water. Twenty-four hours later, embryos were screened using a fluorescent microscope to ensure consistent engraftment sizes. Successfully transplanted embryos were placed in tanks to grow or treated with drugs, as described later. For further details about the transplantation procedure, see Supplemental Experimental Procedures.

In Vivo Drug Treatment

Transplants were randomly distributed into two treatment groups: DMSO or drug (AZD6244 or U0126). Embryos were placed in 12-well plates, 10–12 per well in 0.5 mL of egg water with either DMSO or 50 μM drug, and plates were moved to 28°C. Treatments were refreshed daily for 5 days. Embryos were imaged and rinsed with egg water, and each treatment group was combined and placed in separate tanks to grow for 8 weeks. At 9 wpf, fish were screened by fluorescence microscopy for presence of a tumor mass and euthanized with Tricaine-S. For further details about both in vivo and ex vivo drug treatment, see Supplemental Experimental Procedures.

Transplant Quantification

Fluorescent images of tumor transplants were acquired on the fifth day of treatment (8 dpf). Tumor area for each embryo was quantified using ImageJ. For each treatment, the average tumor area was calculated after removing the smallest and largest numbers (to control for outliers). Average tumor area for DMSO-treated embryos was set to 100% for each experiment. The human CNS-PNET rank-ordered gene list was generated from the GEO: GSE80768 dataset (eight OLIG2/SOX10 high CNS PNETs and seven normal fetal brains). To generate heatmaps, human genes were ranked based on fold change. Human genes that were not present in the zebrafish dataset (i.e., human ortholog not present in zebrafish) were removed. The top 60 up- and downregulated genes were then selected for comparison to zebrafish (i.e., human ortholog not present in zebrafish) were removed. The top 60 up- and downregulated genes were then selected for comparison to zebrafish tumors (RNA-seq datasets from zebrafish tumors and control brains can be accessed via GEO: GSE80768). Zebrafish tumor and normal brain gene expression with p < 0.05 was represented using mean centered log2 FPKM (fragments per kilobase of exon per million fragments mapped) values. For further details about RNA-seq analysis and the generation of heatmaps, see Supplemental Experimental Procedures.

GSEA, Heatmaps, and PCA

Rank lists for GSEA were generated using zebrafish normal brain (n = 8) versus tumor (n = 7) and human normal brain versus CNS-PNETs (GEO: GSE14295; 26 CNS_PNETs and 7 normal fetal brains). Analysis was performed using GSEA v2.2.2 (http://www.broadinstitute.org/gsea).

The human CNS-PNET rank-ordered gene list was generated from the GEO: GSE14295 dataset (eight OLIG2/SOX10 high CNS PNETs and seven normal fetal brains). To generate heatmaps, human genes were ranked based on fold change. Human genes that were not present in the zebrafish dataset (i.e., human ortholog not present in zebrafish) were removed. The top 60 up- and downregulated genes were then selected for comparison to zebrafish tumors (RNA-seq datasets from zebrafish tumors and control brains can be accessed via GEO: GSE80768). Zebrafish tumor and normal brain gene expression with p < 0.05 was represented using mean centered log2 FPKM (fragments per kilobase of exon per million fragments mapped) values. For further details about RNA-seq analysis and the generation of heatmaps, see Supplemental Experimental Procedures.

PCA of human and zebrafish samples was performed based on published gene lists defining CNS-PNET subtypes (Picard et al., 2012; Sturm et al., 2016). Human microarray expression (GEO: GSE14295 and GSE73038) and zebrafish RNA-seq FKPM values were log2 transformed and then mean centered and scaled by sample. PCA data were generated using the R function prcomp (R 3.2.2) with centering and scaling turned off. Plots show the scores for the first two principal components.

Western Analysis, Immunohistochemistry, Cloning, and Image Acquisition and Processing

Phospho-p44/42 MAPK (Erk1/2)(Thr202/Tyr204) antibody (cat. no. 9101) from Cell Signaling Technology was used in immunohistochemistry on human and zebrafish tumor samples. For detailed procedures, see the Supplemental Experimental Procedures.

Statistical Analysis

The statistical calculations were performed using GraphPad Prism software. The Mantel-Cox test was used to calculate the statistical significance of animal survival data. The Student’s t test was used to evaluate statistical significance for embryonic transplant quantification and drug treatment survival. Error bars represent ± SEM.


